OMICS International to organise third international conference and exhibition on biowaivers, biologics and biosimilars from October 27 to 29 at HICC, Hyderabad. Through this event they aim to explore the current challenges and opportunities in making the lifesaving biological medicines cost effective, so that they are affordable to millions of needy patients that are unable to meet the growing healthcare expenditure.

Two workshops also are being organised by Dr Shivraj Dasari, CSO of SLS Cell Culture Technologies and Dr Rajiv Dahiya, president, association of pharmacy professionals at this scientific conference. This event is expected to boost the participant’s industry knowledge and enhance relationships by networking industrialists and academic leaders.

OMICS and TiE will jointly conduct a session on investment opportunities in biosimilars and biologics in Hyderabad. Murali Bhukkapatnam, managing director GDH workforce would be one of the keynote speakers. Biosimilars-2014 will provide an excellent global opportunity to the scientists, partners and pharma leaders from biopharmaceutical and biotechnology industries to innovate and to explore the strategic market of biologics and biosimilars.

Biosimilars-2014 is collaborated with Doctor of Pharmacy Association (DPA, Patent Agent Association (PAAi), Association of Biotechnology and Pharmacy, Association of Pharmacy Professionals, BioFocus Research Center and Association of Pharmaceutical Teachers in India.

The conference with the theme current challenges and opportunities in cost effective and affordable biosimilars, highlights the challenges and regulatory approach for biosimilars; emerging biosimilars in therapeutics; clinical studies and clinician’s prospects for biosimilars; globalization of biosimilars; biosimilars innovator pharmaceutical products; analytical strategies; bioequivalence assessment; BCS and IVIVC based biowaivers; plant produced biosimilar products and pharmacovigilance and its challenges etc.

Biowaivers is an exemption granted to the biopharmaceutical companies to a particular bioequivalent product. The patent expirations of generics have given a gateway to biosimilars into the global pharmaceutical economy for the past few years. Biosimilars is a biopharmaceutical drug designed to have active properties similar to the one that has previously been licensed. Biologics are biological medical products made or derived from the active drug substance of a living organism by recombination of DNA or controlled gene expression methods.

Biosimilar medicines are follow-on versions of original biological medicines. They are independently developed after the patent protecting the original product has expired. Biosimilar medicines are intended to have the same mechanism of action as the original biological medicines, and are designed to treat the same diseases as the innovator’s product.

For further details contact: Lakshmi Padmini, Biosimilars-2014 Organizing Committee, Biosimilars2014@omicsonline.us: Ph: 040-47482284